LabCorp Announces New Term Loan Facility

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 3, 2019-- On June 3, 2019 , LabCorp® (NYSE: LH) entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million (the “New Term Loan Facility”). Bank of America, N.A.

LabCorp and Envigo Complete Innovative Transactions

LabCorp Acquires Envigo’s Global Nonclinical Contract Research Business, Envigo Acquires LabCorp’s Covance Research Products Business BURLINGTON, N.C. & INDIANAPOLIS --(BUSINESS WIRE)--Jun. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding

LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer

New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing BURLINGTON, N.C. --(BUSINESS WIRE)--May 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the

LabCorp to Webcast Its Annual Meeting of Shareholders

BURLINGTON, N.C. --(BUSINESS WIRE)--May 2, 2019-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019 , at 9:00 a.m. Eastern Daylight Time via the Company website at www.LabCorp.com . An archived replay of the audio webcast will be

LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance

Q1 revenue of $2.79 billion , down 2% from $2.85 billion last year Q1 diluted EPS of $1.86 , up 11% from $1.67 last year; Q1 adjusted EPS of $2.62 , down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45 , from $11.00 to $11.40 2019 free cash flow guidance of $950

LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider

LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United